Trial Outcomes & Findings for A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (NCT NCT06097663)
NCT ID: NCT06097663
Last Updated: 2026-04-09
Results Overview
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
31 participants
Primary outcome timeframe
Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Results posted on
2026-04-09
Participant Flow
Participants were randomized in a 4:4:4:1:1 ratio to one of the five treatment sequences.
The study consisted of a screening period up to 30 days.
Participant milestones
| Measure |
Treatment Sequence 1
On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
Treatment Sequence 2
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 3
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 4
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.
|
Treatment Sequence 5
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
11
|
8
|
8
|
2
|
2
|
|
Overall Study
PD analysis set
|
11
|
8
|
8
|
2
|
2
|
|
Overall Study
Safety analysis set
|
11
|
8
|
8
|
2
|
2
|
|
Overall Study
PK analysis set
|
11
|
7
|
7
|
2
|
0
|
|
Overall Study
COMPLETED
|
11
|
7
|
5
|
2
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
1
|
3
|
0
|
1
|
Reasons for withdrawal
| Measure |
Treatment Sequence 1
On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
Treatment Sequence 2
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 3
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 4
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.
|
Treatment Sequence 5
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
1
|
2
|
0
|
0
|
|
Overall Study
Subject Decision
|
0
|
0
|
1
|
0
|
1
|
Baseline Characteristics
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Baseline characteristics by cohort
| Measure |
Treatment Sequence 1
n=11 Participants
On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
Treatment Sequence 2
n=8 Participants
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 3
n=8 Participants
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.
|
Treatment Sequence 4
n=2 Participants
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.
|
Treatment Sequence 5
n=2 Participants
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
|
Total
n=31 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=36 Participants
|
0 Participants
n=78 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=23 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=36 Participants
|
1 Participants
n=78 Participants
|
3 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
1 Participants
n=24 Participants
|
8 Participants
n=23 Participants
|
|
Age, Categorical
>=65 years
|
8 Participants
n=36 Participants
|
7 Participants
n=78 Participants
|
5 Participants
n=23 Participants
|
2 Participants
n=23 Participants
|
1 Participants
n=24 Participants
|
23 Participants
n=23 Participants
|
|
Age, Continuous
|
68.9 years
STANDARD_DEVIATION 6.44 • n=36 Participants
|
70.3 years
STANDARD_DEVIATION 5.92 • n=78 Participants
|
70.3 years
STANDARD_DEVIATION 7.27 • n=23 Participants
|
76.0 years
STANDARD_DEVIATION 5.66 • n=23 Participants
|
65.5 years
STANDARD_DEVIATION 6.36 • n=24 Participants
|
69.8 years
STANDARD_DEVIATION 6.40 • n=23 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=36 Participants
|
2 Participants
n=78 Participants
|
3 Participants
n=23 Participants
|
1 Participants
n=23 Participants
|
0 Participants
n=24 Participants
|
7 Participants
n=23 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=36 Participants
|
6 Participants
n=78 Participants
|
5 Participants
n=23 Participants
|
1 Participants
n=23 Participants
|
2 Participants
n=24 Participants
|
24 Participants
n=23 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
0 Participants
n=36 Participants
|
1 Participants
n=78 Participants
|
1 Participants
n=23 Participants
|
0 Participants
n=23 Participants
|
0 Participants
n=24 Participants
|
2 Participants
n=23 Participants
|
|
Race/Ethnicity, Customized
White
|
11 Participants
n=36 Participants
|
7 Participants
n=78 Participants
|
7 Participants
n=23 Participants
|
2 Participants
n=23 Participants
|
2 Participants
n=24 Participants
|
29 Participants
n=23 Participants
|
PRIMARY outcome
Timeframe: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)Population: Participants in the pharmacodynamic (PD) analysis set with available data for the outcome measure. In this analysis, MAS825 data are excluded from the analysis (including placebo sessions following a MAS825 dose), in alignment with the primary objectives of the protocol and the corresponding statistical analysis plan.
Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.
Outcome measures
| Measure |
DFV890 10 mg
n=9 Participants
Participants received DFV890 10 mg within the study
|
DFV890 25 mg
n=15 Participants
Participants received DFV890 25 mg within the study
|
DFV890 50 mg
n=9 Participants
Participants received DFV890 50 mg within the study
|
DFV890 100 mg
n=14 Participants
Participants received DFV890 100 mg within the study
|
Placebo
n=17 Participants
Participants received Placebo within the study
|
|---|---|---|---|---|---|
|
Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
|
0.8602 ratio serum levels of IL-6
Interval 0.7117 to 1.0397
|
0.7558 ratio serum levels of IL-6
Interval 0.6615 to 0.8637
|
0.7002 ratio serum levels of IL-6
Interval 0.6146 to 0.7976
|
0.6657 ratio serum levels of IL-6
Interval 0.5495 to 0.8064
|
1.1219 ratio serum levels of IL-6
Interval 0.9594 to 1.312
|
PRIMARY outcome
Timeframe: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)Population: Participants in the pharmacodynamic (PD) analysis set with available data for the outcome measure. In this analysis, MAS825 data are excluded from the analysis (including placebo sessions following a MAS825 dose), in alignment with the primary objectives of the protocol and the corresponding statistical analysis plan.
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
Outcome measures
| Measure |
DFV890 10 mg
n=9 Participants
Participants received DFV890 10 mg within the study
|
DFV890 25 mg
n=15 Participants
Participants received DFV890 25 mg within the study
|
DFV890 50 mg
n=9 Participants
Participants received DFV890 50 mg within the study
|
DFV890 100 mg
n=14 Participants
Participants received DFV890 100 mg within the study
|
Placebo
n=17 Participants
Participants received Placebo within the study
|
|---|---|---|---|---|---|
|
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model
|
0.9088 ratio serum levels of IL-18
Interval 0.8825 to 0.9358
|
0.9087 ratio serum levels of IL-18
Interval 0.8825 to 0.9357
|
0.9087 ratio serum levels of IL-18
Interval 0.8825 to 0.9357
|
0.9087 ratio serum levels of IL-18
Interval 0.8825 to 0.9357
|
0.9767 ratio serum levels of IL-18
Interval 0.9427 to 1.0119
|
PRIMARY outcome
Timeframe: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.Population: Participants in the pharmacodynamic (PD) analysis set with available data for the outcome measure. In this analysis, measurements of IL-6 on MAS825 data are managed considering the effect after 3 weeks from dosing.
Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.
Outcome measures
| Measure |
DFV890 10 mg
n=11 Participants
Participants received DFV890 10 mg within the study
|
DFV890 25 mg
n=17 Participants
Participants received DFV890 25 mg within the study
|
DFV890 50 mg
Participants received DFV890 50 mg within the study
|
DFV890 100 mg
Participants received DFV890 100 mg within the study
|
Placebo
Participants received Placebo within the study
|
|---|---|---|---|---|---|
|
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model
|
0.5406 ratio serum levels if IL-6
Interval 0.4287 to 0.6818
|
1.1335 ratio serum levels if IL-6
Interval 0.9488 to 1.3541
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignmentPopulation: Participants in the pharmacokinetic (PK) analysis set. DFV890 concentrations in serum were analyzed only for DFV890-treated participants with an available value after three weeks of dosing.
Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.
Outcome measures
| Measure |
DFV890 10 mg
n=5 Participants
Participants received DFV890 10 mg within the study
|
DFV890 25 mg
n=10 Participants
Participants received DFV890 25 mg within the study
|
DFV890 50 mg
n=6 Participants
Participants received DFV890 50 mg within the study
|
DFV890 100 mg
n=9 Participants
Participants received DFV890 100 mg within the study
|
Placebo
Participants received Placebo within the study
|
|---|---|---|---|---|---|
|
Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state
|
144 ng/mL
Standard Deviation 72.7
|
427 ng/mL
Standard Deviation 363
|
1200 ng/mL
Standard Deviation 914
|
2730 ng/mL
Standard Deviation 3930
|
—
|
SECONDARY outcome
Timeframe: Day 22, Day 43, Day 64 and Day 85Population: Participants in the pharmacokinetic (PK) analysis set. MAS825 concentrations in serum were summarized only for MAS825-treated participants with an available concentration value at Day 22, 43, 64 and 85 respectively.
MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.
Outcome measures
| Measure |
DFV890 10 mg
n=11 Participants
Participants received DFV890 10 mg within the study
|
DFV890 25 mg
Participants received DFV890 25 mg within the study
|
DFV890 50 mg
Participants received DFV890 50 mg within the study
|
DFV890 100 mg
Participants received DFV890 100 mg within the study
|
Placebo
Participants received Placebo within the study
|
|---|---|---|---|---|---|
|
MAS825 Serum Concentrations
Day 22
|
35750.0 ng/mL
Standard Deviation 8360.62
|
—
|
—
|
—
|
—
|
|
MAS825 Serum Concentrations
Day 43
|
22285.7 ng/mL
Standard Deviation 9080.64
|
—
|
—
|
—
|
—
|
|
MAS825 Serum Concentrations
Day 64
|
10574.0 ng/mL
Standard Deviation 4346.20
|
—
|
—
|
—
|
—
|
|
MAS825 Serum Concentrations
EOT (Day 85)
|
7790.0 ng/mL
Standard Deviation 4403.56
|
—
|
—
|
—
|
—
|
Adverse Events
DFV890 10 mg
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
DFV890 25 mg
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
DFV890 50 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
DFV890 100 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
MAS825
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Placebo Sessions
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Placebo Participants
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
DFV890 100 mg Follow-up
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
MAS825 Follow-up
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Placebo Follow-up
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
DFV890 10 mg
n=10 participants at risk
Participants that received DFV890 10 mg within the study
|
DFV890 25 mg
n=16 participants at risk
Participants that received DFV890 10 mg within the study
|
DFV890 50 mg
n=9 participants at risk
Participants that received DFV890 10 mg within the study
|
DFV890 100 mg
n=16 participants at risk
Participants that received DFV890 100 mg within the study
|
MAS825
n=11 participants at risk
Participants that received a single s.c. dose of MAS825
|
Placebo Sessions
n=22 participants at risk
Participants that received placebo in the dosing periods
|
Placebo Participants
n=18 participants at risk
Participants that received placebo within the study
|
DFV890 100 mg Follow-up
n=16 participants at risk
Participants in the follow-up phase after completing the 12-week treatment ending with DFV890 100 mg
|
MAS825 Follow-up
n=11 participants at risk
Participants in the follow-up phase after completing the 12-week treatment ending with DFV890 100 mg
|
Placebo Follow-up
n=2 participants at risk
Participants in the follow-up phase after completing the 12-week treatment ending with placebo
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Ear and labyrinth disorders
Deafness
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Eye disorders
Eye haematoma
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Eye disorders
Eyelids pruritus
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
General disorders and administration site conditions
Fatigue
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
General disorders and administration site conditions
Injection site haematoma
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
General disorders and administration site conditions
Malaise
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Infections and infestations
Bacterial infection
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
11.1%
1/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
2/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
11.1%
2/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Investigations
Amylase increased
|
10.0%
1/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Investigations
Lipase increased
|
10.0%
1/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
2/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
11.1%
2/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
9.1%
1/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
11.1%
1/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
11.1%
1/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Nervous system disorders
Headache
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
18.2%
2/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Skin and subcutaneous tissue disorders
Itching scar
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
4.5%
1/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
5.6%
1/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Vascular disorders
Hot flush
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
|
Vascular disorders
Hypertension
|
0.00%
0/10 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
6.2%
1/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/9 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/22 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/18 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/16 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/11 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
0.00%
0/2 • Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.
Number at risk was based on total number of unique participants for each DFV890 or MAS825 dose level. For placebo, since one participant could have multiple placebo dosing periods, the number at risk was defined by total number of participants in each placebo dosing period, counting multiple AEs in the same period once. Overall, 22 participants in placebo dosing periods corresponded to 18 unique participants at risk.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
- Publication restrictions are in place
Restriction type: OTHER